Bugs, hosts and ICU environment: Countering pan-resistance in nosocomial microbiota and treating bacterial infections in the critical care setting

Revista Espanola de Anestesiologia y Reanimacion

Volumn 61, Issue 3, 2014, Pages

  Maseda, Emilio ^a   Mensa, José ^b   Valía, Juan Carlos ^c   Gomez Herreras, José Ignacio ^d   Ramasco, Fernando ^e   Samso, Enric ^f   Chiveli, Miguel Angel ^g   Pereira, Jorge ^h   González, Rafael ⁱ   Aguilar, Gerardo ^j   Tamayo, Gonzalo ^k   Ojeda, Nazario ^l   Rico, Jesús ^m   Giménez, María José ⁿ   Aguilar, Lorenzo ⁿ  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^d HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

^e HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^f HOSPITAL DEL MAR   (Spain)

^g HOSPITAL UNIVERSITARIO LA FE   (Spain)

^h Anesthesiology and Surgical Critical Care Department   (Spain)

ⁱ HOSPITAL DE LEÓN   (Spain)

^j HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^k HOSPITAL DE CRUCES   (Spain)

^l HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

^m HOSPITAL UNIVERSITARIO RÍO HORTEGA   (Spain)

ⁿ PRISM AG   (Spain)

more..

Author keywords

Acinetobacter baumannii; Critical care; Extended spectrum lactamase; Methicillin resistant Staphylococcus aureus; Pseudomonas aeruginosa; Vancomycin resistant enterococci

Indexed keywords

ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; BACTERIAL INFECTIONS; CROSS INFECTION; DISEASE CARRIER; HOST PATHOGEN INTERACTION; HUMAN; INTENSIVE CARE UNIT; MICROBIOLOGY; MICROFLORA; PHENOTYPE; RISK FACTOR; SPECIES DIFFERENCE; SURGICAL WOUND INFECTION;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CROSS INFECTION; DISEASE RESERVOIRS; DRUG RESISTANCE, MICROBIAL; HOST-PATHOGEN INTERACTIONS; HUMANS; INTENSIVE CARE UNITS; MICROBIOTA; PHENOTYPE; RISK FACTORS; SPECIES SPECIFICITY; SURGICAL WOUND INFECTION;

EID: 84894654183     PISSN: 00349356     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.redar.2013.11.012     Document Type: Short Survey

References (170)

1. Martínez J.L., Baquero F. Interactions among strategies associated with bacterial infection: pathogenicity, epidemicity, and antibiotic resistance. Clin Microbiol Rev 2002, 15:647-679.
2. Baquero F. Environmental stress and evolvability in microbial systems. Clin Microbiol Infect 2009, 15(Suppl. 1):5-10.
3. Hawkey P.M. The growing burden of antimicrobial resistance. J Antimicrob Chemother 2008, 62(Suppl. 1):i1-i9.
4. Baquero M.R., Galán J.C., del Carmen Turrientes M., Cantón R., Coque T.M., Martínez J.L., et al. Increased mutation frequencies in Escherichia coli isolates harboring extended-spectrum beta-lactamases. Antimicrob Agents Chemother 2005, 49:4754-4756.
5. Ubeda C., Maiques E., Knecht E., Lasa I., Novick R.P., Penadés J.R. Antibiotic-induced SOS response promotes horizontal dissemination of pathogenicity island-encoded virulence factors in staphylococci. Mol Microbiol 2005, 56:836-844.
6. Giménez M., García-Rey C., Barberán J., Aguilar L. Clinical experience with tigecycline in the treatment of nosocomial infections caused by isolates exhibiting prevalent resistance mechanisms. Rev Esp Quimioter 2009, 22:48-56. [Article in Spanish].
7. Graffunder E.M., Preston K.E., Evans A.M., Venezia R.A. Risk factors associated with extended-spectrum beta-lactamase-producing organisms at a tertiary care hospital. J Antimicrob Chemother 2005, 56:139-145.
8. Lautenbach E., Weiner M.G., Nachamkin I., Bilker W.B., Sheridan A., Fishman N.O. Imipenem resistance among Pseudomonas aeruginosa isolates: risk factors for infection and impact of resistance on clinical and economic outcomes. Infect Control Hosp Epidemiol 2006, 27:893-900.
9. Martínez J.A., Aguilar J., Almela M., Marco F., Soriano A., López F., et al. Prior use of carbapenems may be a significant risk factor for extended-spectrum beta-lactamase-producing Escherichia coli or Klebsiella spp. in patients with bacteraemia. J Antimicrob Chemother 2006, 58:1082-1085.
10. Vincent J.L., Rello J., Marshall J., Silva E., Anzueto A., Martin C.D., et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009, 302:2323-2329.
11. Bueno-Cavanillas A., Delgado-Rodríguez M., López-Luque A., Schaffino-Cano S., Gálvez-Vargas R. Influence of nosocomial infection on mortality rate in an intensive care unit. Crit Care Med 1994, 22:55-60.
12. McKenzie C. Antibiotic dosing in critical illness. J Antimicrob Chemother 2011, 66(Suppl. 2):ii25-ii31.
13. Pittet D. Infection control and quality health care in the new millennium. Am J Infect Control 2005, 33:258-267.
14. Vincent J.L., Sakr Y., Sprung C.L., Ranieri V.M., Reinhart K., Gerlach H., et al. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 2006, 34:344-353.
15. Malacarne P., Langer M., Nascimben E., Moro M.L., Giudici D., Lampati L., et al. Building a continuous multicenter infection surveillance system in the intensive care unit: findings from the initial data set of 9,493 patients from 71 Italian intensive care units. Crit Care Med 2008, 36:1105-1113.
16. Malacarne P., Boccalatte D., Acquarolo A., Agostini F., Anghileri A., Giardino M., et al. Epidemiology of nosocomial infection in 125 Italian intensive care units. Minerva Anestesiol 2010, 76:13-23.
17. Grundmann H., Aires-de-Sousa M., Boyce J., Tiemersma E. Emergence and resurgence of meticillin-resistant Staphylococcus aureus as a public-health threat. Lancet 2006, 368:874-885.
18. Olaechea P.M., Insausti J., Blanco A., Luque P. Epidemiología e impacto de las infecciones nosocomiales. Med Intensiva 2010, 34:256-267. [Article in Spanish].
19. Hall I.M., Barrass I., Leach S., Pittet D., Hugonnet S. Transmission dynamics of methicillin-resistant Staphylococcus aureus in a medical intensive care unit. J R Soc Interface 2012, 9:2639-2652.
20. Schweickert B., Geffers C., Farragher T., Gastmeier P., Behnke M., Eckmanns T., et al. The MRSA-import in ICUs is an important predictor for the occurrence of nosocomial MRSA cases. Clin Microbiol Infect 2011, 17:901-906.
21. Nair N., Kourbatova E., Poole K., Huckabee C.M., Murray P., Huskins W.C., et al. Molecular epidemiology of methicillin-resistant Staphylococcus aureus (MRSA) among patients admitted to adult intensive care units: the STAR*ICU trial. Infect Control Hosp Epidemiol 2011, 32:1057-1063.
22. Leclercq R. Epidemiological and resistance issues in multidrug-resistant staphylococci and enterococci. Clin Microbiol Infect 2009, 15:224-231.
23. Tacconelli E. Antimicrobial use: risk driver of multidrug resistant microorganisms in healthcare settings. Curr Opin Infect Dis 2009, 22:352-358.
24. Dancer S.J. The effect of antibiotics on methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 2008, 61:246-253.
25. Ginn A.N., Wiklendt A.M., Gidding H.F., George N., O'Driscoll J.S., Partridge S.R., et al. The ecology of antibiotic use in the ICU: homogeneous prescribing of cefepime but not tazocin selects for antibiotic resistant infection. PLoS ONE 2012, 7:e38719.
26. Appelbaum P.C. The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. Clin Microbiol Infect 2006, 12(Suppl. 1):16-23.
27. French G.L. Bactericidal agents in the treatment of MRSA infections-the potential role of daptomycin. J Antimicrob Chemother 2006, 58:1107-1117.
28. Howe R.A., Monk A., Wootton M., Walsh T.R., Enright M.C. Vancomycin susceptibility within methicillin-resistant Staphylococcus aureus lineages. Emerg Infect Dis 2004, 10:855-857.
29. Liu C., Chambers H.F. Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods. Antimicrob Agents Chemother 2003, 47:3040-3045.
30. Khosrovaneh A., Riederer K., Saeed S., Tabriz M.S., Shah A.R., Hanna M.M., et al. Frequency of reduced vancomycin susceptibility and heterogeneous subpopulation in persistent or recurrent methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2004, 38:1328-1330.
31. Tenover F.C., Moellering R.C. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis 2007, 44:1208-1215.
32. Campanile F., Borbone S., Perez M., Bongiorno D., Cafiso V., Bertuccio T., et al. Heteroresistance to glycopeptides in Italian meticillin-resistant Staphylococcus aureus (MRSA) isolates. Int J Antimicrob Agents 2010, 36:415-419.
33. Holmes N.E., Johnson P.D., Howden B.P. Relationship between vancomycin-resistant Staphylococcus aureus, vancomycin-intermediate S. aureus, high vancomycin MIC, and outcome in serious S. aureus infections. J Clin Microbiol 2012, 50:2548-2552.
34. Aguilar L., Giménez M.J., Barberán J. Glycopeptide heteroresistance and tolerance in hospital grampositive isolates: "invisible" phenomena to the clinician with clinical implications?. Rev Esp Quimioter 2009, 22:173-179. [Article in Spanish].
35. Bourgeois I., Pestel-Caron M., Lemeland J.F., Pons J.L., Caron F. Tolerance to the glycopeptides vancomycin and teicoplanin in coagulase-negative staphylococci. Antimicrob Agents Chemother 2007, 51:740-743.
36. Jones R.N. Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains. Clin Infect Dis 2006, 42(Suppl. 1):S13-S24.
37. Gonzalez N., Sevillano D., Alou L., Cafini F., Gimenez M.J., Gomez-Lus M.L., et al. Influence of the MBC/MIC ratio on the antibacterial activity of vancomycin versus linezolid against methicillin-resistant Staphylococcus aureus isolates in a pharmacodynamic model simulating serum and soft tissue interstitial fluid concentrations reported in diabetic patients. J Antimicrob Chemother 2013, 68:2291-2295.
38. Traczewski M.M., Katz B.D., Steenbergen J.N., Brown S.D. Inhibitory and bactericidal activities of daptomycin, vancomycin, and teicoplanin against methicillin-resistant Staphylococcus aureus isolates collected from 1985 to 2007. Antimicrob Agents Chemother 2009, 53:1735-1738.
39. Alder J., Eisenstein B. The advantage of bactericidal drugs in the treatment of infection. Curr Infect Dis Rep 2004, 6:251-253.
40. González C., Rubio M., Romero-Vivas J., González M., Picazo J.J. Bacteremic pneumonia due to Staphylococcus aureus: a comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clin Infect Dis 1999, 29:1171-1177.
41. Cafini F., Aguilar L., González N., Giménez M.J., Torrico M., Alou L., et al. In vitro effect of the presence of human albumin or human serum on the bactericidal activity of daptomycin against strains with the main resistance phenotypes in Gram-positives. J Antimicrob Chemother 2007, 59:1185-1189.
42. Maor Y., Hagin M., Belausov N., Keller N., Ben-David D., Rahav G. Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia. J Infect Dis 2009, 199:619-624.
43. Howden B.P., Johnson P.D., Ward P.B., Stinear T.P., Davies J.K. Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2006, 50:3039-3047.
44. Soriano A., Marco F., Martínez J.A., Pisos E., Almela M., Dimova V.P., et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008, 46:193-200.
45. Picazo J.J., Betriu C., Culebras E., Rodríguez-Avial I., Gómez M., López F., et al. Activity of daptomycin against staphylococci collected from bloodstream infections in Spanish medical centers. Diagn Microbiol Infect Dis 2009, 64:448-451.
46. Hidayat L.K., Hsu D.I., Quist R., Shriner K.A., Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006, 166:2138-2144.
47. Bosso J.A., Nappi J., Rudisill C., Wellein M., Bookstaver P.B., Swindler J., et al. Relationship between vancomycin trough concentrations and nephrotoxicity: a prospective multicenter trial. Antimicrob Agents Chemother 2011, 55:5475-5479.
48. Gould I.M. The problem with glycopeptides. Int J Antimicrob Agents 2007, 30:1-3.
49. Jones R.N. Key considerations in the treatment of complicated staphylococcal infections. Clin Microbiol Infect 2008, 14(Suppl. 2):3-9.
50. Schramm G.E., Johnson J.A., Doherty J.A., Micek S.T., Kollef M.H. Methicillin-resistant Staphylococcus aureus sterile-site infection: the importance of appropriate initial antimicrobial treatment. Crit Care Med 2006, 34:2069-2074.
51. Charles P.G., Ward P.B., Johnson P.D., Howden B.P., Grayson M.L. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis 2004, 38:448-451.
52. Howden B.P. Recognition and management of infections caused by vancomycin-intermediate Staphylococcus aureus (VISA) and heterogenous VISA (hVISA). Intern Med J 2005, 35(Suppl. 2):S136-S140.
53. Bae I.G., Federspiel J.J., Miró J.M., Woods C.W., Park L., Rybak M.J., et al. Heterogeneous vancomycin-intermediate susceptibility phenotype in bloodstream methicillin-resistant Staphylococcus aureus isolates from an international cohort of patients with infective endocarditis: prevalence, genotype, and clinical significance. J Infect Dis 2009, 200:1355-1366.
54. May J., Shannon K., King A., French G. Glycopeptide tolerance in Staphylococcus aureus. J Antimicrob Chemother 1998, 42:189-197.
55. Sakoulas G., Moise-Broder P.A., Schentag J., Forrest A., Moellering R.C., Eliopoulos G.M. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004, 42:2398-2402.
56. Hidron A.I., Edwards J.R., Patel J., Horan T.C., Sievert D.M., Pollock D.A., et al. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 2008, 29:996-1011.
57. Saribas S., Bagdatli Y. Vancomycin tolerance in enterococci. Chemotherapy 2004, 50:250-254.
58. Arias C.A., Murray B.E. The rise of the Enterococcus: beyond vancomycin resistance. Nat Rev Microbiol 2012, 10:266-278.
59. Werner G., Coque T.M., Hammerum A.M., Hope R., Hryniewicz W., Johnson A., et al. Emergence and spread of vancomycin resistance among enterococci in Europe. Euro Surveill 2008, 13.
60. Sader H.S., Watters A.A., Fritsche T.R., Jones R.N. Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005). BMC Infect Dis 2007, 7:29.
61. Top J., Willems R., Blok H., de Regt M., Jalink K., Troelstra A., et al. Ecological replacement of Enterococcus faecalis by multiresistant clonal complex 17 Enterococcus faecium. Clin Microbiol Infect 2007, 13:316-319.
62. Warren D.K., Kollef M.H., Seiler S.M., Fridkin S.K., Fraser V.J. The epidemiology of vancomycin-resistant Enterococcus colonization in a medical intensive care unit. Infect Control Hosp Epidemiol 2003, 24:257-263.
63. Pan S.C., Wang J.T., Chen Y.C., Chang Y.Y., Chen M.L., Chang S.C. Incidence of and risk factors for infection or colonization of vancomycin-resistant enterococci in patients in the intensive care unit. PLoS ONE 2012, 7:e47297.
64. Batistão D.W., Gontijo-Filho P.P., Conceição N., Oliveira A.G., Ribas R.M. Risk factors for vancomycin-resistant enterococci colonisation in critically ill patients. Mem Inst Oswaldo Cruz 2012, 107:57-63.
65. Sydnor E.R., Perl T.M. Hospital epidemiology and infection control in acute-care settings. Clin Microbiol Rev 2011, 24:141-173.
66. Rivera A.M., Boucher H.W. Current concepts in antimicrobial therapy against select gram-positive organisms: methicillin-resistant Staphylococcus aureus, penicillin-resistant pneumococci, and vancomycin-resistant enterococci. Mayo Clin Proc 2011, 86:1230-1243.
67. Donskey C.J., Schreiber J.R., Jacobs M.R., Shekar R., Salata R.A., Gordon S., et al. A polyclonal outbreak of predominantly VanB vancomycin-resistant enterococci in northeast Ohio. Northeast Ohio Vancomycin-Resistant Enterococcus Surveillance Program. Clin Infect Dis 1999, 29:573-579.
68. Kolar M., Urbanek K., Vagnerova I., Koukalova D. The influence of antibiotic use on the occurrence of vancomycin-resistant enterococci. J Clin Pharm Ther 2006, 31:67-72.
69. Song J.Y., Cheong H.J., Jo Y.M., Choi W.S., Noh J.Y., Heo J.Y., et al. Vancomycin-resistant Enterococcus colonization before admission to the intensive care unit: a clinico-epidemiologic analysis. Am J Infect Control 2009, 37:734-740.
70. Kelesidis T., Tewhey R., Humphries R.M. Evolution of high-level daptomycin resistance in Enterococcus faecium during daptomycin therapy is associated with limited mutations in the bacterial genome. J Antimicrob Chemother 2013, 68:1926-1928.
71. Scheetz M.H., Knechtel S.A., Malczynski M., Postelnick M.J., Qi C. Increasing incidence of linezolid-intermediate or -resistant, vancomycin-resistant Enterococcus faecium strains parallels increasing linezolid consumption. Antimicrob Agents Chemother 2008, 52:2256-2259.
72. Dobbs T.E., Patel M., Waites K.B., Moser S.A., Stamm A.M., Hoesley C.J. Nosocomial spread of Enterococcus faecium resistant to vancomycin and linezolid in a tertiary care medical center. J Clin Microbiol 2006, 44:3368-3370.
73. Kainer M.A., Devasia R.A., Jones T.F., Simmons B.P., Melton K., Chow S., et al. Response to emerging infection leading to outbreak of linezolid-resistant enterococci. Emerg Infect Dis 2007, 13:1024-1030.
74. Ntokou E., Stathopoulos C., Kristo I., Dimitroulia E., Labrou M., Vasdeki A., et al. Intensive care unit dissemination of multiple clones of linezolid-resistant Enterococcus faecalis and Enterococcus faecium. J Antimicrob Chemother 2012, 67:1819-1823.
75. Moellering R.C. The Garrod Lecture. The Enterococcus: a classic example of the impact of antimicrobial resistance on therapeutic options. J Antimicrob Chemother 1991, 28:1-12.
76. Safdar A., Rolston K.V. Vancomycin tolerance, a potential mechanism for refractory gram-positive bacteremia observational study in patients with cancer. Cancer 2006, 106:1815-1820.
77. Lentino J.R., Narita M., Yu V.L. New antimicrobial agents as therapy for resistant gram-positive cocci. Eur J Clin Microbiol Infect Dis 2008, 27:3-15.
78. Singh S.R., Bacon A.E., Young D.C., Couch K.A. In vitro 24-hour time-kill studies of vancomycin and linezolid in combination versus methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2009, 53:4495-4497.
79. Steenbergen J.N., Mohr J.F., Thorne G.M. Effects of daptomycin in combination with other antimicrobial agents: a review of in vitro and animal model studies. J Antimicrob Chemother 2009, 64:1130-1138.
80. Souli M., Galani I., Giamarellou H. Emergence of extensively drug-resistant and pandrug-resistant Gram-negative bacilli in Europe. Euro Surveill 2008, 13. pii: 19045.
81. Livermore D.M. Fourteen years in resistance. Int J Antimicrob Agents 2012, 39:283-294.
82. Díaz M.A., Hernández-Bello J.R., Rodríguez-Baño J., Martínez-Martínez L., Calvo J., Blanco J., et al. Diversity of Escherichia coli strains producing extended-spectrum beta-lactamases in Spain: second nationwide study. J Clin Microbiol 2010, 48:2840-2845.
83. Cantón R., Loza E., Aznar J., Calvo J., Cercenado E., Cisterna R., et al. Antimicrobial susceptibility of Gram-negative organisms from intraabdominal infections and evolution of isolates with extended spectrum β-lactamases in the SMART study in Spain (2002-2010). Rev Esp Quimioter 2011, 24:223-232.
84. Rubio-Perez I., Martin-Perez E., Garcia D.D., Calvo M.L., Barrera E.L. Extended-spectrum beta-lactamase-producing bacteria in a tertiary care hospital in Madrid: epidemiology, risk factors and antimicrobial susceptibility patterns. Emerg Health Threats J 2012, 5.
85. Paterson D.L., Bonomo R.A. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 2005, 18:657-686.
86. Hombach M., Mouttet B., Bloemberg G.V. Consequences of revised CLSI and EUCAST guidelines for antibiotic susceptibility patterns of ESBL- and AmpC β-lactamase-producing clinical Enterobacteriaceae isolates. J Antimicrob Chemother 2013, 68:2092-2098.
87. Rodríguez-Baño J., Navarro M.D., Romero L., Muniain M.A., de Cueto M., Ríos M.J., et al. Bacteremia due to extended-spectrum beta -lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge. Clin Infect Dis 2006, 43:1407-1414.
88. Dunne W.M., Hardin D.J. Use of several inducer and substrate antibiotic combinations in a disk approximation assay format to screen for AmpC induction in patient isolates of Pseudomonas aeruginosa, Enterobacter spp., Citrobacter spp., and Serratia spp. J Clin Microbiol 2005, 43:5945-5949.
89. Livermore D.M., Brown D.F. Detection of beta-lactamase-mediated resistance. J Antimicrob Chemother 2001, 48(Suppl. 1):59-64.
90. Chow J.W., Fine M.J., Shlaes D.M., Quinn J.P., Hooper D.C., Johnson M.P., et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991, 115:585-590.
91. Park Y.S., Yoo S., Seo M.R., Kim J.Y., Cho Y.K., Pai H. Risk factors and clinical features of infections caused by plasmid-mediated AmpC beta-lactamase-producing Enterobacteriaceae. Int J Antimicrob Agents 2009, 34:38-43.
92. Livermore D.M., Brown D.F., Quinn J.P., Carmeli Y., Paterson D.L., Yu V.L. Should third-generation cephalosporins be avoided against AmpC-inducible Enterobacteriaceae?. Clin Microbiol Infect 2004, 10:84-85.
93. Harris P.N., Ferguson J.K. Antibiotic therapy for inducible AmpC β-lactamase-producing Gram-negative bacilli: what are the alternatives to carbapenems, quinolones and aminoglycosides?. Int J Antimicrob Agents 2012, 40:297-305.
94. Mushtaq S., Irfan S., Sarma J.B., Doumith M., Pike R., Pitout J., et al. Phylogenetic diversity of Escherichia coli strains producing NDM-type carbapenemases. J Antimicrob Chemother 2011, 66:2002-2005.
95. Palzkill T. Metallo-β-lactamase structure and function. Ann N Y Acad Sci 2013, 1277:91-104.
96. Wybo I., De Bel A., Soetens O., Echahidi F., Vandoorslaer K., Van Cauwenbergh M., et al. Differentiation of cfiA-negative and cfiA-positive Bacteroides fragilis isolates by matrix-assisted laser desorption ionization-time of flight mass spectrometry. J Clin Microbiol 2011, 49:1961-1964.
97. Bonomo R.A., Szabo D. Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin Infect Dis 2006, 43(Suppl. 2):S49-S56.
98. Livermore D.M. Has the era of untreatable infections arrived?. J Antimicrob Chemother 2009, 64(Suppl. 1):i29-i36.
99. Walsh T.R. Clinically significant carbapenemases: an update. Curr Opin Infect Dis 2008, 21:367-371.
100. Suarez C., Peña C., Campo A., Murillas J., Almirante B., Pomar V., et al. Impact of carbapenem resistance on Pseudomonas aeruginosa (PA) bloodstream infections outcome. 49th interscience conference on antimicrobial agents and chemotherapy 2009, [Abstract K-332].
101. Georges B., Conil J.M., Dubouix A., Archambaud M., Bonnet E., Saivin S., et al. Risk of emergence of Pseudomonas aeruginosa resistance to beta-lactam antibiotics in intensive care units. Crit Care Med 2006, 34:1636-1641.
102. Girlich D., Naas T., Nordmann P. Biochemical characterization of the naturally occurring oxacillinase OXA-50 of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2004, 48:2043-2048.
103. Lopez-Otsoa F., Gallego L., Towner K.J., Tysall L., Woodford N., Livermore D.M. Endemic carbapenem resistance associated with OXA-40 carbapenemase among Acinetobacter baumannii isolates from a hospital in northern Spain. J Clin Microbiol 2002, 40:4741-4743.
104. Da Silva G.J., Quinteira S., Bértolo E., Sousa J.C., Gallego L., Duarte A., et al. Long-term dissemination of an OXA-40 carbapenemase-producing Acinetobacter baumannii clone in the Iberian Peninsula. J Antimicrob Chemother 2004, 54:255-258.
105. Picazo J.J., Betriu C., Rodríguez-Avial I., Culebras E., Gómez M., López F., et al. Antimicrobial resistance surveillance: VIRA STUDY 2006. Enferm Infecc Microbiol Clin 2006, 24:617-628. [Article in Spanish].
106. Kluytmans-Vandenbergh M.F., Kluytmans J.A., Voss A. Dutch guideline for preventing nosocomial transmission of highly resistant microorganisms (HRMO). Infection 2005, 33:309-313.
107. Cisneros J.M., Rodríguez-Baño J., Fernández-Cuenca F., Ribera A., Vila J., Pascual A., et al. Risk-factors for the acquisition of imipenem-resistant Acinetobacter baumannii in Spain: a nationwide study. Clin Microbiol Infect 2005, 11:874-879.
108. del Mar Tomas M., Cartelle M., Pertega S., Beceiro A., Llinares P., Canle D., et al. Hospital outbreak caused by a carbapenem-resistant strain of Acinetobacter baumannii: patient prognosis and risk-factors for colonisation and infection. Clin Microbiol Infect 2005, 11:540-546.
109. Castanheira M., Mendes R.E., Woosley L.N., Jones R.N. Trends in carbapenemase-producing Escherichia coli and Klebsiella spp. from Europe and the Americas: report from the SENTRY antimicrobial surveillance programme (2007-09). J Antimicrob Chemother 2011, 66:1409-1411.
110. Cantón R., Akóva M., Carmeli Y., Giske C.G., Glupczynski Y., Gniadkowski M., et al. Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. Clin Microbiol Infect 2012, 18:413-431.
111. Sánchez-Romero I., Asensio A., Oteo J., Muñoz-Algarra M., Isidoro B., Vindel A., et al. Nosocomial outbreak of VIM-1-producing Klebsiella pneumoniae isolates of multilocus sequence type 15: molecular basis, clinical risk factors, and outcome. Antimicrob Agents Chemother 2012, 56:420-427.
112. Miró E., Segura C., Navarro F., Sorlí L., Coll P., Horcajada J.P., et al. Spread of plasmids containing the bla(VIM-1) and bla(CTX-M) genes and the qnr determinant in Enterobacter cloacae, Klebsiella pneumoniae and Klebsiella oxytoca isolates. J Antimicrob Chemother 2010, 65:661-665.
113. Tato M., Coque T.M., Ruíz-Garbajosa P., Pintado V., Cobo J., Sader H.S., et al. Complex clonal and plasmid epidemiology in the first outbreak of Enterobacteriaceae infection involving VIM-1 metallo-beta-lactamase in Spain: toward endemicity?. Clin Infect Dis 2007, 45:1171-1178.
114. Cendejas E., Gómez-Gil R., Gómez-Sánchez P., Mingorance J. Detection and characterization of Enterobacteriaceae producing metallo-beta-lactamases in a tertiary-care hospital in Spain. Clin Microbiol Infect 2010, 16:181-183.
115. Curiao T., Morosini M.I., Ruiz-Garbajosa P., Robustillo A., Baquero F., Coque T.M., et al. Emergence of bla KPC-3-Tn4401a associated with a pKPN3/4-like plasmid within ST384 and ST388 Klebsiella pneumoniae clones in Spain. J Antimicrob Chemother 2010, 65:1608-1614.
116. Solé M., Pitart C., Roca I., Fàbrega A., Salvador P., Muñoz L., et al. First description of an Escherichia coli strain producing NDM-1 carbapenemase in Spain. Antimicrob Agents Chemother 2011, 55:4402-4404.
117. Struelens M.J., Monnet D.L., Magiorakos A.P., Santos O'Connor F., Giesecke J. European NDM-1 Survey Participants. New Delhi metallo-beta-lactamase 1-producing Enterobacteriaceae: emergence and response in Europe. Euro Surveill 2010, 15.
118. European Center for Disease Prevention and Control Antimicrobial resistance surveillance in Europe 2011, Available at: http://ecdc.europa.eu/en/publications/Publications/antimicrobial-resistance-surveillance-europe-2011.pdf.
119. Falagas M.E., Rafailidis P.I., Kofteridis D., Virtzili S., Chelvatzoglou F.C., Papaioannou V., et al. Risk factors of carbapenem-resistant Klebsiella pneumoniae infections: a matched case control study. J Antimicrob Chemother 2007, 60:1124-1130.
120. Patel G., Huprikar S., Factor S.H., Jenkins S.G., Calfee D.P. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 2008, 29:1099-1106.
121. Gupta N., Limbago B.M., Patel J.B., Kallen A.J. Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention. Clin Infect Dis 2011, 53:60-67.
122. Schwaber M.J., Klarfeld-Lidji S., Navon-Venezia S., Schwartz D., Leavitt A., Carmeli Y. Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality. Antimicrob Agents Chemother 2008, 52:1028-1033.
123. Daikos G.L., Petrikkos P., Psichogiou M., Kosmidis C., Vryonis E., Skoutelis A., et al. Prospective observational study of the impact of VIM-1 metallo-beta-lactamase on the outcome of patients with Klebsiella pneumoniae bloodstream infections. Antimicrob Agents Chemother 2009, 53:1868-1873.
124. Dellinger R.P., Levy M.M., Rhodes A., Annane D., Gerlach H., Opal S.M., et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013, 39:165-228.
125. Martinez M.N., Papich M.G., Drusano G.L. Dosing regimen matters: the importance of early intervention and rapid attainment of the pharmacokinetic/pharmacodynamic target. Antimicrob Agents Chemother 2012, 56:2795-2805.
126. Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. Procedimientos en Microbiología Clínica. Análisis farmacocinéticofarmacodinámico en Microbiología: herramienta para evaluar el tratamiento antimicrobiano http://www.seimc.org/documentos/protocolos/microbiologia/.
127. Scaglione F., Paraboni L. Pharmacokinetics/pharmacodynamics of antibacterials in the Intensive Care Unit: setting appropriate dosing regimens. Int J Antimicrob Agents 2008, 32:294-301.
128. Alou L., Aguilar L., Sevillano D., Giménez M.J., Echeverría O., Gómez-Lus M.L., et al. Is there a pharmacodynamic need for the use of continuous versus intermittent infusion with ceftazidime against Pseudomonas aeruginosa? An in vitro pharmacodynamic model. J Antimicrob Chemother 2005, 55:209-213.
129. Lorente L., Jiménez A., Martín M.M., Iribarren J.L., Jiménez J.J., Mora M.L. Clinical cure of ventilator-associated pneumonia treated with piperacillin/tazobactam administered by continuous or intermittent infusion. Int J Antimicrob Agents 2009, 33:464-468.
130. Lorente L., Lorenzo L., Martín M.M., Jiménez A., Mora M.L. Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli. Ann Pharmacother 2006, 40:219-223.
131. Rello J., Sole-Violan J., Sa-Borges M., Garnacho-Montero J., Muñoz E., Sirgo G., et al. Pneumonia caused by oxacillin-resistant Staphylococcus aureus treated with glycopeptides. Crit Care Med 2005, 33:1983-1987.
132. DiMondi V.P., Rafferty K. Review of continuous-infusion vancomycin. Ann Pharmacother 2013, 47:219-227.
133. Spapen H.D., Janssen van Doorn K., Diltoer M., Verbrugghe W., Jacobs R., Dobbeleir N., et al. Retrospective evaluation of possible renal toxicity associated with continuous infusion of vancomycin in critically ill patients. Ann Intensive Care 2011, 1:26.
134. Rayner C.R., Forrest A., Meagher A.K., Birmingham M.C., Schentag J.J. Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clin Pharmacokinet 2003, 42:1411-1423.
135. Buerger C., Plock N., Dehghanyar P., Joukhadar C., Kloft C. Pharmacokinetics of unbound linezolid in plasma and tissue interstitium of critically ill patients after multiple dosing using microdialysis. Antimicrob Agents Chemother 2006, 50:2455-2463.
136. Adembri C., Fallani S., Cassetta M.I., Arrigucci S., Ottaviano A., Pecile P., et al. Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion. Int J Antimicrob Agents 2008, 31:122-129.
137. Ratjen F., Rietschel E., Kasel D., Schwiertz R., Starke K., Beier H., et al. Pharmacokinetics of inhaled colistin in patients with cystic fibrosis. J Antimicrob Chemother 2006, 57:306-311.
138. Michalopoulos A.S., Falagas M.E. Colistin: recent data on pharmacodynamics properties and clinical efficacy in critically ill patients. Ann Intensive Care 2011, 1:30.
139. Pea F., Viale P., Furlanut M. Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin Pharmacokinet 2005, 44:1009-1034.
140. Erstad B.L. Dosing of medications in morbidly obese patients in the intensive care unit setting. Intensive Care Med 2004, 30:18-32.
141. Pereira J.M., Paiva J.A. Antimicrobial drug interactions in the critically ill patients. Curr Clin Pharmacol 2013, 8:25-38.
142. Palomar M., Vaque J., Alvarez Lerma F., Pastor V., Olaechea P., Fernández-Crehuet J. Nosocomial infection indicators. Med Clin (Barc) 2008, 131(Suppl. 3):48-55. [Article in Spanish].
143. Strausbaugh L.J. Nosocomial respiratory infections. Mandell, Douglas, Bennett's principles and practice of infectious diseases 2005, 3362-3370. Elsevier Inc., Philadelphia. 6th ed. G.L. Mandell, J.E. Bennett, R. Dolin (Eds.).
144. Esperatti M., Ferrer M., Theessen A., Liapikou A., Valencia M., Saucedo L.M., et al. Nosocomial pneumonia in the intensive care unit acquired by mechanically ventilated versus nonventilated patients. Am J Respir Crit Care Med 2010, 182:1533-1539.
145. Sandiumenge A., Rello J. Ventilator-associated pneumonia caused by ESKAPE organisms: cause, clinical features, and management. Curr Opin Pulm Med 2012, 18:187-193.
146. Maseda Garrido E., Alvarez J., Garnacho-Montero J., Jerez V., Lorente L., Rodríguez O. Update on catheter-related bloodstream infections in ICU patients. Enferm Infecc Microbiol Clin 2011, 29(Suppl. 4):10-15.
147. Olaechea P.M., Palomar M., Álvarez-Lerma F., Otal J.J., Insausti J., López-Pueyo M.J., et al. Morbidity and mortality associated with primary and catheter-related bloodstream infections in critically ill patients. Rev Esp Quimioter 2013, 26:21-29.
148. Orsi G.B., Franchi C., Marrone R., Giordano A., Rocco M., Venditti M. Laboratory confirmed bloodstream infection aetiology in an intensive care unit: eight years study. Ann Ig 2012, 24:269-278.
149. Diekema D.J., Beekmann S.E., Chapin K.C., Morel K.A., Munson E., Doern G.V. Epidemiology and outcome of nosocomial and community-onset bloodstream infection. J Clin Microbiol 2003, 41:3655-3660.
150. Beekmann S.E., Henderson D.K. Infections caused by percutaneous intravascular devices. Mandell, Douglas, Bennett's principles and practice of infectious diseases 2005, 3347-3362. Elsevier Inc, Philadelphia. 6th ed. G.L. Mandell, J.E. Bennett, R. Dolin (Eds.).
151. Rodríguez-Créixems M., Muñoz P., Martín-Rabadán P., Cercenado E., Guembe M., Bouza E. Evolution and aetiological shift of catheter-related bloodstream infection in a whole institution: the microbiology department may act as a watchtower. Clin Microbiol Infect 2012, 19:845-851.
152. Tabah A., Koulenti D., Laupland K., Misset B., Valles J., Bruzzi de Carvalho F., et al. Characteristics and determinants of outcome of hospital-acquired bloodstream infections in intensive care units: the EUROBACT International Cohort Study. Intensive Care Med 2012, 38:1930-1945.
153. Sancho S., Artero A., Zaragoza R., Camarena J.J., González R., Nogueira J.M. Impact of nosocomial polymicrobial bloodstream infections on the outcome in critically ill patients. Eur J Clin Microbiol Infect Dis 2012, 31:1791-1796.
154. Rodríguez-Baño J., Picón E., Gijón P., Hernández J.R., Cisneros J.M., Peña C., et al. Risk factors and prognosis of nosocomial bloodstream infections caused by extended-spectrum-beta-lactamase-producing Escherichia coli. J Clin Microbiol 2010, 48:1726-1731.
155. López M.J., Cortés J.A. Urinary tract colonization and infection in critically ill patients. Med Intensiva 2012, 36:143-151.
156. Richards M.J., Edwards J.R., Culver D.H., Gaynes R.P. Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Crit Care Med 1999, 27:887-892.
157. Warren J.W. Nosocomial urinary tract infections. Mandell, Douglas, Bennett's principles and practice of infectious diseases 2005, 3370-3381. Elsevier Inc, Philadelphia. 6th ed. G.L. Mandell, J.E. Bennett, R. Dolin (Eds.).
158. Frakking F.N., Rottier W.C., Dorigo-Zetsma J.W., van Hattem J.M., van Hees B.C., Kluytmans J.A., et al. Appropriateness of empirical treatment and outcome in bacteremia caused by extended-spectrum β-lactamase producing bacteria. Antimicrob Agents Chemother 2013, 57:3092-3099.
159. Mojtahedzadeh M., Panahi Y., Fazeli M.R., Najafi A., Pazouki M., Navehsi B.M., et al. Intensive care unit-acquired urinary tract infections in patients admitted with sepsis: etiology, risk factors, and patterns of antimicrobial resistance. Int. J Infect Dis 2008, 12:312-318.
160. Röhrborn A., Wacha H., Schöffel U., Billing A., Aeberhard P., Gebhard B., et al. Coverage of enterococci in community acquired secondary peritonitis: results of a randomized trial. Surg Infect (Larchmt) 2000, 1:95-107.
161. Gauzit R., Péan Y., Barth X., Mistretta F., Lalaude O. Epidemiology, management, and prognosis of secondary non-postoperative peritonitis: a French prospective observational multicenter study. Surg Infect (Larchmt) 2009, 10:119-127. Top Study Team.
162. Cercenado E., Torroba L., Cantón R., Martínez-Martínez L., Chaves F., García-Rodríguez J.A., et al. Multicenter study evaluating the role of enterococci in secondary bacterial peritonitis. J Clin Microbiol 2010, 48:456-459.
163. Fariñas M.C., Llinares P., Almirante B., Barberán J., de Dios Colmenero J., Garau J., et al. New trends in infective endocarditis. Enferm Infecc Microbiol Clin 2011, 29(Suppl. 4):22-35.
164. Fernández Guerrero M.L., Goyenechea A., Verdejo C., Roblas R.F., de Górgolas M. Enterococcal endocarditis on native and prosthetic valves: a review of clinical and prognostic factors with emphasis on hospital-acquired infections as a major determinant of outcome. Medicine (Baltimore) 2007, 86:363-377.
165. Pierce D., Calkins B.C., Thornton K. Infectious endocarditis: diagnosis and treatment. Am Fam Phys 2012, 85:981-986.
166. Naber C.K., Erbel R. Infective endocarditis with negative blood cultures. Int J Antimicrob Agents 2007, 30(Suppl. 1):S32-S36.
167. Tornos P., Gonzalez-Alujas T., Thuny F., Habib G. Infective endocarditis: the European viewpoint. Curr Probl Cardiol 2011, 36:175-222.
168. Murdoch D.R., Corey G.R., Hoen B., Miró J.M., Fowler V.G., Bayer A.S., et al. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study. Arch Intern Med 2009, 169:463-473.
169. Talbot T.R., Kaiser A.B. Post-operative infections and antimicrobial prophylaxis. Mandell, Douglas, Bennett's principles and practice of infectious diseases 2005, 3533-3547. Elsevier Inc., Philadelphia. 6th ed. G.L. Mandell, J.E. Bennett, R. Dolin (Eds.).
170. Razazi K., Derde L.P., Verachten M., Legrand P., Lesprit P., Brun-Buisson C. Clinical impact and risk factors for colonization with extended-spectrum β-lactamase-producing bacteria in the intensive care unit. Intensive Care Med 2012, 38:1769-1778.